Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.…
Faron Pharmaceuticals LTD: Holding(s) in Company
Faron Pharmaceuticals (HEL: FARON) is listed on Nasdaq Helsinki, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 36 employees.
The shares were at 0.3160 EUR on 20 November 2026, down 86.9% over 52 weeks. Its 52-week range is 0.3040 EUR to 2.415 EUR: the price is 86.9% below the high and 3.9% above the low.
Its market capitalisation is 64.11M EUR.
Faron Pharmaceuticals reports return on equity of 147.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 14.06M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 1.262 EUR is 299.5% above the current price. The next earnings report is expected on 3 March 2027.